skip to Main Content

Immunotherapy for MSI-High Pancreatic Tumors

Newsfeed image, light gray text on dark gray background
John L. Marshall, MD; Tanios S. Bekaii-Saab, MD; Kabir Mody, MD; Eileen M. O’Reilly, MD; and George P. Kim, MD, share their experiences of using pembrolizumab in patients with MSI-high pancreatic tumors and discuss the management of immune-related adverse events associated with immunotherapy.

Listen here . . .

Back To Top